Premarket Bulls: Cubist Pharmaceuticals (NASDAQ:CBST), Spectrum Pharmaceuticals, (NASDAQ:SPPI), Sequenom, (NASDAQ:SQNM), Progenics Pharmaceuticals, (NASDAQ:PGNX), Ballard Power Systems (NASDAQ:BLDP)

Posted by on Jun 24, 2014

Cubist Pharmaceuticals Inc. (NASDAQ:CBST) antibacterial drug Sivextro was approved by the U.S. Food and Drug Administration Friday for treatment of adult acute bacterial skin and skin structure infections. Cubist Pharmaceuticals Inc. (NASDAQ:CBST) stock opened today at $72.99 and is currently trading at $73.83. The stock showed a positive weekly performance of 5.14%.

Spectrum Pharmaceuticals (NASDAQ:SPPI), a biotechnology company with fully integrated commercial and drug development operations and with a primary focus in Hematology and Oncology, on 28 may announced that the key phase 2 trial of its long-acting granulocyte stimulating factor analog developed using LAPSCOVERY technology (SPI-2012) has completed its Phase 2 study enrollment; this positions Spectrum for Phase 3 decision making before year end. Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) stock opened at $8.30, in current trading session and currently is at $8.40, by gaining 3.07%. The 52 week range of $6.36 – $10.32. Company’s market capitalization is 551.45 million.

William Blair raised the life sciences company’s stock to “outperform” from “market perform”. Sequenom Inc. (NASDAQ:SQNM) was executing on multiple fronts and “a more secure cash situation” from sale of its genetic analysis business earlier this month, analysts said. Sequenom, Inc. (NASDAQ:SQNM) stock is currently trading at $3.65. The EPS of the stock is -0.81. Company’s market capitalization is 425.42 million.

As previously reported in the proxy materials for its 2014 Annual Meeting of Stockholders held on June 17, Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Board of Directors previously approved, subject to stockholder approval, and its stockholders approved at the Annual Meeting, amendment of the Company’s 2005 Stock Incentive Plan to extend its expiration date to March 25, 2024 and increase the number of common shares available for issuance from 10,450,000 to 11,450,000. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) stock opened the session at $4.35, and now is at $4.31. The 52 week range of the Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) stock remained $3.10 – $7.45 and the day range was $4.25 – $4.37.

Ballard Power Systems Inc. (USA) (NASDAQ:BLDP) on June 19 announced the signing of a definitive agreement with Azure Hydrogen (Azure) in relation to an assembly license for Telecom Backup Power systems for the China market. The agreement has a value of approximately $6 million over the 2014-15 period. Ballard Power Systems Inc. (USA) (NASDAQ:BLDP) stock opened today at $4.33 and is currently trading at $4.19. The stock showed a positive weekly performance of 25.59%.

Leave a Reply

Your email address will not be published. Required fields are marked *